CytoDyn Announces Humanized Cytolin(R) Provisional Patent Application Filed for the Treatment of HIV/AIDS

LUTZ, Fla.--(BUSINESS WIRE)--CytoDyn Inc. (the “Company”) (OTC:CYDY), a biotechnology company focused on the development of new therapies for combating infection with immune deficiency viruses, HIV/AIDS, announced today that it has filed a provisional patent application in the United States for its humanized version of its lead product Cytolin®, a monoclonal antibody for the treatment of HIV infection. According to Dr. Richard Trauger, a co-inventor on the provisional patent application and Managing Director of Science of the Company, “The provisional patent application discloses the use of a humanized version of Cytolin®. We hope this invention will not only allow for the treatment of HIV infection but also for the potential inhibition of HIV infection. If issued, we believe the patent will further strengthen the Company's intellectual property portfolio.” Kenneth J. Van Ness, President and Chief Executive Officer of the Company commented that, “we are pleased to have reached this significant milestone for the Company. We believe this new antibody provides the Company with a clinical candidate for Phase I testing and will be supplied to Dr. Eric S. Rosenberg at Massachusetts General Hospital ('MGH'). The Company anticipates that the humanized version of the monoclonal antibody will be included in the extended study that the Company is funding at MGH regarding the potential mechanism of action of Cytolin®.”